Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Oden6570on Dec 16, 2024 6:38am
201 Views
Post# 36363637

Just as excited about the Bacteria progress ! Tick Tock !

Just as excited about the Bacteria progress ! Tick Tock !TLD-1433 also is clinically used against several cancers [9]. Given its current usage and effectiveness against bacteria, we tested whether it also was effective against several human pathogenic viruses. We found that nanomolar concentrations of TLD-1433 were effective in inactivating >99 % of IAV, human CoV OC-43, Zika virus and herpes virus (Figs. 2 and 8). Inactivation was very rapid; it required only seconds of exposure to light activation

Hence, the viral inactivation mediated by TLD-1433-PDT-induced ROS is effective against different families of viruses, not only enveloped but also non-enveloped, via lipid peroxidation and potentially other mechanisms. Immune recognition structures appear to remain intact during this inactivation. This opens potential opportunity to generate a broad spectrum of inactivated virus(es) vaccines with greater potency than vaccines pro duced by currently available inactivation techniques.


Nanomolar_Concentrations_of_the_Photodynamic_Compo.pdf

<< Previous
Bullboard Posts
Next >>